Dermavant Sciences Inc.
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. Our mission is to make healthier skin a reality for the millions of people around the world living with chronic skin conditions. That’s why we’re hard at work developing novel treatments that deliver groundbreaking science exactly where patients need it — their skin. Because skin is more than superficial — it’s where we live, every moment of every day.
3780 Kilroy Airport
Suite 250
Long Beach, CA 90806 US
Suite 250
Long Beach, CA 90806 US
NEWS
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.
Companies bolstered their leadership with additions to boards of directors and c-suite offices.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.
JOBS
IN THE PRESS